Ipsen Gestione

Criteri Gestione verificati 2/4

Ipsen Il CEO è David Loew, nominato in Jul2020, e ha un mandato di 6.08 anni. la retribuzione annua totale è € 10.42M, composta da 9.8% di stipendio e 90.2% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.11% delle azioni della società, per un valore di € 13.69M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4 anni e 11.3 anni.

Informazioni chiave

David Loew

Amministratore delegato

€10.4m

Compenso totale

Percentuale dello stipendio del CEO	9.84%
Mandato del CEO	6.1yrs
Proprietà del CEO	0.1%
Durata media del management	4yrs
Durata media del Consiglio di amministrazione	11.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di David Loew rispetto agli utili di Ipsen?
Data	Compenso totale	Stipendio	Utili della società
Jun 30 2026	n/a	n/a	€513m
Mar 31 2026	n/a	n/a	€478m
Dec 31 2025	€10m	€1m	€444m
Sep 30 2025	n/a	n/a	€446m
Jun 30 2025	n/a	n/a	€448m
Mar 31 2025	n/a	n/a	€402m
Dec 31 2024	€5m	€1m	€356m
Jun 30 2024	n/a	n/a	€664m
Mar 31 2024	n/a	n/a	€641m
Dec 31 2023	€4m	€988k	€617m
Jun 30 2023	n/a	n/a	€406m
Mar 31 2023	n/a	n/a	€500m
Dec 31 2022	€4m	€950k	€593m
Sep 30 2022	n/a	n/a	€656m
Jun 30 2022	n/a	n/a	€719m
Mar 31 2022	n/a	n/a	€675m
Dec 31 2021	€5m	€950k	€631m
Sep 30 2021	n/a	n/a	€626m
Jun 30 2021	n/a	n/a	€622m
Mar 31 2021	n/a	n/a	€585m
Dec 31 2020	€5m	€475k	€548m

Compensazione vs Mercato: La retribuzione totale di David ($USD 12.02M ) è superiore alla media delle aziende di dimensioni simili nel mercato UK ($USD 7.51M ).

Compensazione vs guadagni: La retribuzione di David è aumentata di oltre il 20% nell'ultimo anno.

AMMINISTRATORE DELEGATO

David Loew (59 yo)

6.1yrs

Mandato

€10,417,318

Compensazione

Mr. David Loew has been the Chief Executive Officer & MD of Ipsen S.A. since July 1, 2020 and serves as its Director since May 28, 2020. Mr. Loew served as an Executive Vice President of Sanofi Pasteur at...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
David Loew	MD, CEO & Director	6.1yrs	€10.42m	0.11% € 13.7m
Aymeric Le Chatelier	Executive VP & CFO	11.8yrs	€1.02m	Nessun dato
Pierrick Lefranc	Executive VP & Head of Technical Operations	less than a year	Nessun dato	Nessun dato
Henry Wheeler	Global Vice President of Investor Relations	no data	Nessun dato	Nessun dato
Caroline Sitbon	Executive VP & General Counsel	less than a year	Nessun dato	Nessun dato
Sally Bain	Head of Global Media Relations	no data	Nessun dato	Nessun dato
Regis Mulot	Executive VP & Chief Human Resources Officer	8.4yrs	Nessun dato	Nessun dato
Philippe Lopes-Fernandes	Executive VP & Chief Business Officer	5.8yrs	Nessun dato	Nessun dato
Mari Scheiffele	Executive VP	4.8yrs	Nessun dato	Nessun dato
Sandra Silvestri	Executive VP & Chief Medical Officer	3.3yrs	Nessun dato	Nessun dato
Christelle Huguet	Executive VP and Head of R&D	2.9yrs	Nessun dato	Nessun dato
Josep Catlla	Executive VP & Chief Corporate Affairs Officer	2yrs	Nessun dato	Nessun dato

4.0yrs

Durata media

57yo

Età media

Gestione esperta: Il team dirigenziale di IPNP è considerato esperto (durata media dell'incarico 4 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
David Loew	MD, CEO & Director	6.3yrs	€10.42m	0.11% € 13.7m
Marc M. de Garidel	Non-Executive Chairman	15.8yrs	€600.00k	0.16% € 21.2m
Margaret Liu	Independent Director	9.2yrs	€170.00k	0.00084% € 108.5k
Michèle Ollier	Director	11.3yrs	€110.95k	0.00061% € 78.8k
Antoine Flochel	Vice Chairman	21yrs	€189.32k	0.0037% € 472.6k
Anne Beaufour	Director	21yrs	€60.00k	26.61% € 3.4b
Piet Wigerinck	Independent Director	no data	€135.00k	Nessun dato
Carol Xueref	Director	14.2yrs	€170.35k	0.00061% € 78.8k
Philippe Bonhomme	Director	14.6yrs	€155.00k	Nessun dato
Catherine-Annick Bradley	Independent Director	less than a year	Nessun dato	Nessun dato
Laetitia Ducroquet	Employees Representative Director	5.8yrs	Nessun dato	0.0016% € 211.8k
Naomi Binoche	Employee Representative Director	4.3yrs	Nessun dato	0.0042% € 543.7k

11.3yrs

Durata media

62.5yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di IPNP è composto da personale esperto e esperto (durata media dell'incarico 11.3 anni).

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2026/08/14 08:14
Prezzo dell'azione a fine giornata	2026/07/30 00:00
Utili	2026/06/30
Utili annuali	2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Ipsen S.A. è coperta da 27 analisti. 12 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Richard Silver	Barclays
Charles Pitman	Barclays
Yihan Li	Barclays

Ipsen Gestione

Criteri Gestione verificati 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Ipsen Announces Appointment of Catherine Bradley, CBE, as an Independent Director, Chair of the Audit Committee and Member of the Compensation Committee, Effective July 29, 2026

Ipsen S.A., Annual General Meeting, May 13, 2026

Ipsen Announces Executive Changes

Ipsen Nominates Peter Guenter to its Board of Directors, Effective January 28, 2026

Ipsen Announces Executive Changes

Ipsen Announces Demise of Board Member Henri Beaufour on November 28, 2025

Recent updates

First half 2026 earnings released: EPS: €4.89 (vs €4.04 in 1H 2025)

Ipsen Announces Appointment of Catherine Bradley, CBE, as an Independent Director, Chair of the Audit Committee and Member of the Compensation Committee, Effective July 29, 2026

Ipsen Provides Update On Phase III BOLD Trial In Biliary Atresia

Ipsen Reports Positive Topline Phase III Results for Dysport in Both Episodic and Chronic Migraine

Ipsen S.A. (ENXTPA:IPN) entered into a definitive merger agreement to acquire Kartos Therapeutics, Inc. for $1.8 billion.

Ipsen Presents New Late-Breaking Results and Real-World Evidence for IQIRVO in Primary Biliary Cholangitis

Ipsen Announces Late-Breaking Data from First Head-To-Head Study Comparing Dysport and Botox in Adults with Upper Limb Spasticity

Dividend increased to €1.60

Ipsen Presents First-In-Class Phase II Corabotase Data In Glabellar Lines

Ipsen Unveils Corabotase, First-In-Class Recombinant Neuroinhibitor RNI

Ipsen S.A., Annual General Meeting, May 13, 2026

Ipsen Showcases Transformative Potential of Early Immuno-Oncology Pipeline At AACR

Ipsen Announces Executive Changes

Ipsen Voluntarily Withdraws Tazverik in Follicular Lymphoma and Epithelioid Sarcoma

Ipsen S.A. to Report First Half, 2026 Results on Jul 30, 2026

Ipsen S.A. Provides Earnings Guidance for the Full Year 2026

Ipsen Nominates Peter Guenter to its Board of Directors, Effective January 28, 2026

Ipsen Announces Executive Changes

Ipsen Announces the Presentation of 14 Across Multiple Neurological Conditions At the Toxins 2026 Conference in Madrid, Spain

Ipsen Announces Pivotal Phase II FALKON Trial Do Not Meet Its Primary Endpoint of Reducing New Heterotopic Ossification in Adults and Children Living with Fibrodysplasia Ossificans Progressiva

Ipsen S.A. (ENXTPA:IPN) completed the acquisition of ImCheck Therapeutics SAS from Kurma Partners SA, Gimv NV (ENXTBR:GIMB) and others.

Ipsen Announces Demise of Board Member Henri Beaufour on November 28, 2025

Ipsen S.A. to Report Q4, 2025 Results on Feb 12, 2026

Ipsen Announces That Japan's Ministry of Health, Labour and Welfare Grants Regulatory Approval for Bylvay®? (Odevixibat) for the Treatment of Pruritus Associated with Progressive Familial Intrahepatic Cholestasis

Medison and Ipsen Announces Health Canada Approves Bylvay™? (odevixibat) for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome

Ipsen S.A. Revises Earnings Guidance for the Year 2025

Exelixis, Inc. Partner Ipsen Receives European Commission Approval for CABOMETYX®? (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

Ipsen S.A. Announces New Appointments to Its Executive Committee

Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

Ipsen Announces New Data from Two Late-Breaking Presentations on IQIRVO®? (elafibranor) During the European Association for the Study of the Liver Congress

Ipsen to Present Data from the Late-Breaking Elafibranor in the Investigational Phase II ELMWOOD Study at the European Association for the Study of the Liver (EASL) Congress

Ipsen S.A. Confirms Guidance for the Full-Year 2025

Ipsen S.A. Provides Earnings Guidance for the Year 2025

Ipsen S.A., Annual General Meeting, May 21, 2025

Ipsen S.A. to Report Fiscal Year 2024 Results on Feb 13, 2025

Ipsen Provides Update on CONTACT-02 Phase III Trial in Metastatic Castration-Resistant Prostate Cancer Following Final Overall Survival Analysis

Ipsen Receives CHMPPositive Opinions for Iqirvo® (Elafibranor) in Primary Biliary Cholangitis and Kayfanda® (Odevixibat) in Alagille Syndrome, Two Rare Cholestatic Liver Diseases

Ipsen S.A. Upgrades Earnings Guidance for the Full Year 2024

Genfit S.A. Announces the Successful Corporate Milestone with U.S. FDA Accelerated Approval of Ipsen's Iqirvo for Primary Biliary Cholangitis

Ipsen S.A. Approves Dividend, Payable on 3 June 2024

Ipsen Announces Executive Changes

Dividend of €1.20 announced

Ipsen’s Onivyde Regimen, Potential New Standard-Of-Care First-Line Therapy in Metastatic Pancreatic Adenocarcinoma, Approved by FDA

Full year 2023 earnings released: EPS: €7.79 (vs €7.20 in FY 2022)

Ipsen Announces Latest Phase III Trial Data Investigating Cabometyx®? in Combination with Immunotherapy to Be Present at ASCO Gu 2024

Ipsen Confirms U.S. FDA Grants Priority Review for New Drug Application for Elafibranor for the Treatment of Rare, Cholestatic Liver Disease, PBC

Ipsen and GENFIT Announces Full Results from the Pivotal Phase III ELATIVE Trial

Ipsen S.A. to Report Q4, 2023 Results on Feb 08, 2024

Ipsen S.A. Confirms Sales Guidance for the Fiscal Year 2023

Ipsen S.A., Annual General Meeting, May 28, 2024

IRLAB Therapeutics AB Announces Further Information on Results from Mesdopetam’s Clinical Phase IIb Study in Parkinson’s Disease Levodopa-Induced Dyskinesias and Phase III Preparatory Phase I Studies Performed by Ipsen

New minor risk - Profit margin trend

First half 2023 earnings released: EPS: €2.36 (vs €4.63 in 1H 2022)

Ipsen Provides Update on E.U. Marketing Authorization Application for Bylvay for Cholestatic Pruritus in Patients with Alagille Syndrome

Ipsen Announces European Commission Decision on Palovarotene for the Treatment of FOP

Ipsen and GENFIT Announces Positive Results from Phase III ELATIVE Trial of Elafibranor in Patients with Primary Biliary Cholangitis, A Rare Cholestatic Liver Disease

Ipsen Announces U.S. FDA Submission Acceptance of Its Supplemental New Drug Application for Onivyde Regimen in First-Line Metastatic Pancreatic Ductal Adenocarcinoma

Ipsen Announces U.S. FDA Approves Bylvay® for Patients Living with Cholestatic Pruritus Due to Alagille Syndrome

Ipsen to Present New Data

Ipsen S.A. Approves Dividend, Payable on 6 June 2023

Upcoming dividend of €1.20 per share at 1.1% yield

Ipsen S.A. Proposes Final Dividend for the Financial Year 2022, Payable on June 6, 2023

Full year 2022 earnings released: EPS: €7.20 (vs €7.64 in FY 2021)

Full year 2022 earnings released: EPS: €7.20 (vs €7.82 in FY 2021)

Ipsen S.A. Provides Earnings Guidance for the Full Year 2023

Ipsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U

Ipsen Presents Phase III NAPOLI 3 Trial of Onivyde(R) Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma At Asco GI

Ipsen S.A. to Report Fiscal Year 2022 Results on Feb 09, 2023

Ipsen S.A. to Report Q2, 2023 Results on Jul 27, 2023